Analytical Data
-
Gene name
SARS-CoV-2 S glycoprotein
-
简介
The SARS-CoV-2 S glycoprotein is critical in infection, binding to the ACE2 receptor and allowing viral particles to attach to the host cell membrane. Cleavage of S2/S2′ triggers cell membrane fusion or internalization via endocytosis. Spike glycoProtein Protein, SARS-CoV-2 (HEK293, Strep, His) is the recombinant virus-derived Spike glycoProtein, expressed by HEK293, with Strep, His labeled tag.
- Application
-
Alternative Names
Spike glycoprotein; E2; Peplomer protein; S; Severe acute respiratory syndrome coronavirus 2; 2019-nCoV; Superantigen
-
Species
Virus
-
Source
HEK293
-
Tag
C-Strep;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0DTC2
-
Expression Region
M1-Q1208, K986P, V987P
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SARS-CoV-2, the virus responsible for COVID-19, has a spike (S) glycoprotein that plays a crucial role in its infection mechanism by facilitating binding to the host cell receptor ACE2. Due to its central role in viral entry and immune response, the S glycoprotein is a primary target for vaccine development and therapeutic interventions. Research on recombinant S glycoprotein has gained significant attention, as it allows for the production of the protein in vitro, enabling detailed study of its structure, function, and interactions with neutralizing antibodies. Recombinant forms of the S glycoprotein can be used in serological assays to detect immune responses in vaccinated individuals or those who have recovered from COVID-19. Additionally, understanding the dynamics of the S glycoprotein assists in monitoring viral mutations, such as the emergence of variants, and evaluating vaccine efficacy. The development of recombinant S glycoprotein also facilitates the creation of novel vaccine platforms, including mRNA and viral vector vaccines, which have shown promising results in clinical trials. Overall, the study of recombinant SARS-CoV-2 S glycoprotein is essential to advance our understanding of the virus, enhance vaccine design, and inform public health strategies to combat the pandemic.
